RxDoctor Payments DataLook up a doctor →

Siwen Hu-Lieskovan, MD

Internal Medicine · Los Angeles, CANPI 1578864864

Payments from drug & device makers

$2,941,672in general payments, 2019–2025

Across 278 payments — averaging $10,582 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1.2M
  • E.r. Squibb & Sons, L.L.C.$396K
  • Boehringer Ingelheim$359K
  • Regeneron$323K
  • Pfizer$283K
  • Immunocore Limited$174K
  • plus $163K from 10 others
$13,003in research payments, 2019–2025

Across 7 payments — averaging $1857.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$13K
  • Regeneron$443

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,941,672 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$36,900
Medicare patients
85
Services billed
565

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →